Retraction

Retracted: Hydrostatin-SN10 Ameliorates Pancreatitis-Induced Lung Injury by Affecting IL-6-Induced JAK2/STAT3-Associated Inflammation and Oxidative Stress

Oxidative Medicine and Cellular Longevity

Received 16 December 2020; Accepted 16 December 2020; Published 20 January 2021

Copyright © 2021 Oxidative Medicine and Cellular Longevity. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oxidative Medicine and Cellular Longevity has retracted the article titled “Hydrostatin-SN10 Ameliorates Pancreatitis-Induced Lung Injury by Affecting IL-6-Induced JAK2/STAT3-Associated Inflammation and Oxidative Stress” [1] at the request of the authors due to not acknowledging prior work and errors in the analysis.

Hydrostatin-SN10, derived from Hydrostatin-SN1, was previously described in two Master’s theses that were not cited [2, 3]. Patents held by Yiming Lu and colleagues [4, 5] were not acknowledged and the peptide supplier had a confidentiality agreement with Dr. Lu.

The KD value for SN10 given in the introduction has the wrong unit (μ versus μM) and cannot be relied upon because it was not validated by the use of surface plasmon resonance (SPR) analysis [6] or isothermal titration calorimetry (ITC) [7].

Two control groups should have been included, as noted in [8]: a positive control in the group treated by the SN10 mutant and a negative control in the group treated by the unrelated octapeptide, otherwise the results cannot be stated to have been specifically caused by SN10 treatment. Similar results may be induced by other decapeptides (for example, see [9–11]).

The authors apologized and the editorial board approved the retraction.

References

- [1] X. Piao, Y. Zou, X. Sui et al., “Hydrostatin-SN10 Ameliorates Pancreatitis-Induced Lung Injury by Affecting IL-6-Induced JAK2/STAT3-Associated Inflammation and Oxidative Stress,” *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 9659757, 12 pages, 2019.
- [2] H. Jiang, *Structural optimization and anti-inflammatory mechanism of the anti-inflammatory peptide Hydrostatin-SN1 from sea snake venom* [Master’s thesis], Second Military Medical University, 2016.
- [3] Y. Bian, *The preliminary pharmacodynamic study of selective TNFR1 antagonist peptide Hydrostatin-SN10 in the treatment of inflammatory bowel disease* [Master’s thesis], Shanghai Normal University, 2017.
- [4] Y. Lu, J. Wang, A. Li et al., “Application of Selection TNFR1 Antagonist Peptide SN10 in Preparation of Drugs for Preventing and Treating Rheumatoid Arthritis,” 2018, <https://patents.google.com/patent/US20200188471A1/en>.
- [5] Y. Lu, H. Jiang, Y. Bian et al., “Selective TNFR1 Antagonist Peptide SN10 and Application Thereof in Inflammatory Bowel Disease,” 2018, <https://patents.google.com/patent/US20200277355A1/en>.
- [6] H. Tachibana, K. Koga, Y. Fujimura, and K. Yamada, “A receptor for green tea polyphenol EGCG,” *Nature Structural & Molecular Biology*, vol. 11, no. 4, pp. 380–381, 2004.
- [7] A. Mourão, A. R. Nager, M. V. Nachury, and E. Lorentzen, “Structural basis for membrane targeting of the BBSome by ARL6,” *Nature Structural & Molecular Biology*, vol. 21, no. 12, pp. 1035–1041, 2014.
- [8] K. Hilpert and R. E. W. Hancock, “Use of luminescent bacteria for rapid screening and characterization of short cationic antimicrobial peptides synthesized on cellulose using peptide array technology,” *Nature Protocols*, vol. 2, no. 7, pp. 1652–1660, 2007.
- [9] K. Sowmya, M. I. Bhat, R. K. Bajaj, S. Kapila, and R. Kapila, “Buffalo Milk Casein Derived Decapeptide (YQEPVLGPVR) Having Bifunctional Anti-inflammatory and Antioxidative

Features Under Cellular Milieu,” *International Journal of Peptide Research and Therapeutics*, vol. 25, no. 2, pp. 623–633, 2019.

- [10] M. Namba, M. A. Ghatei, M. Ghiglione, and S. R. Bloom, “Effects of decapeptide of mammalian bombesin and neuro-medin B on pancreatic exocrine secretion in the rat,” *Digestion*, vol. 34, no. 2, pp. 105–114, 1986.
- [11] A. Bourreille, M. Doubremelle, D. R. de la Blétière et al., “RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease,” *Scandinavian Journal of Gastroenterology*, vol. 38, no. 5, pp. 526–532, 2003.